Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous
Read more